Worth separating two things that post #27 runs together.
What I can speak to on semaglutide and gastric emptying is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
5 likes 2mo
Compounds · Semaglutide · continued
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
This follows post #31 rather than contradicting it.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
That is a description of practice, not a recommendation of it.
0 likes 2mo
excursion_check, post #15: Practical note on semaglutide and gastric emptying: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow. Go to post
I would call the community position on semaglutide and gastric emptying likely rather than established, and I would be comfortable defending that hedge.
Picking up post #35: that is the part I would want checked first.
Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.
0 likes 2mo
I had written a reply contradicting post #35 and deleted it. Here is what survived.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
I have kept the units in throughout, for the obvious reason.
21 likes 2mo
k.haddad, post #12: I keep a log for semaglutide and gastric emptying specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it. Go to post
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
Not the answer, but possibly the question that gets there.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
It is a small point and it changes the answer, which is an awkward combination.
0 likes 2mo
Bookmarking this. I will come back when I have something worth adding.
0 likes 2mo
taper_table, post #17: Coming back to post #13, because the follow-up matters more than the original answer. The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for… Go to post
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
p.onwuka, post #27: A definition problem is doing most of the work in this semaglutide and gastric emptying discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small. Go to post
Gallbladder events appear in the labelling for this class and are more common with larger, faster weight reduction. The mechanism is not specific to the drug — rapid weight loss by any route carries the same association.
I keep a log of this specifically because memory is unreliable about it.
Small correction to my own earlier position on semaglutide and gastric emptying. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
1 like 2mo
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
I am reporting what happened, not recommending it.
5 likes 2mo
Confirming post #44 from a second method, which matters more than confirming it from a second person.
Appetite effects and gastrointestinal effects are frequently reported together and are not the same mechanism reported twice. Slowed gastric emptying contributes to both, but central satiety signalling accounts for effects that persist after emptying has normalised.
15 likes 2mo
endpoint_line, post #24: The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier. Go to post
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
JFitzgibbon, post #36: Picking up post #35: that is the part I would want checked first. Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one. Go to post
The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.
Quietly grateful for the plain phrasing. Not every thread gets that.
20 likes 2mo
Post #49 and I disagree about the size of the effect, not about the direction.
Where the semaglutide and gastric emptying reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
0 likes 2mo
The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4 half-lives you are not approaching steady state yet, which is the pharmacological argument for the four-week step interval.
I would put the burden of proof on the interesting explanation, not the dull one.
0 likes 2mo
Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.
20 likes 2mo
t.lindqvist, post #8: Counter-ion form matters for the arithmetic and is almost never stated. A vial labelled 5 mg of peptide as an acetate salt and one labelled 5 mg as trifluoroacetate do not contain the same quantity of the molecule you are interested in. I have written this out at length because the short version keeps being misread. Go to post
Narrowing post #53, because the general version has more than one answer.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
p.iyer_pharmd, post #39: Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing. It is… Go to post
Post #53 put the caveat in the right place and I want to underline it.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
Building on post #53 rather than restating it.
The most useful thing anyone has posted about semaglutide and gastric emptying in this category was a table of what had been measured and by whom. That is what I would want again.
28 likes 2mo
Two claims get bundled together under semaglutide and gastric emptying and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.
Almost every disagreement in threads like this one dissolves once you say which of the two you are making.
14 likes 2mo
i.broberg, post #2: Worth separating two things that the opening post runs together. The most useful reply I ever got about semaglutide and gastric emptying was a request to state my units. It sounds like pedantry and it has saved me twice. Go to post
Same experience here, different supplier, so it is at least not unique to one of them.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
4 likes 2mo
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
0 likes 2mo